Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The case report of Askin's tumor in a 16-year-old girl is focused on the still debatable surgical contg roversy in the treatment of
PNET
tumor, i.e., whether disarticulation of involved rib at the costovertabral joint should be accepted as the mandatory surgical procedure. It was concluded that the procedure, if feasible, may offer better prognosis of
PNET
because progression-free survival rate of patients without costovertebral junction involvement reported in multicenter studies was statistically significantly better than in patients in whom
PNET
has involved the costovertebral junction or
bone metastases
were present at the diagnosis. The cartilage is a natural barrier for tumor spread and this property should be augmented by radical surgery. Disarticulation of involved rib or ribs and pleurectomy should be routinely performed if the surgery is contemplated with proper timing between the cycles of induction chemotherapy.
...
PMID:Costovertebral rib disarticulation and pleurectomy in Askin's tumor: a mandatory approach to radical surgery in children? Case report and guiedelines to surgical treatment. 2251 1
Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/
PNET
) is an aggressive bone tumor. Bone marrow aspiration and biopsy (BMAB) has been recognized as the gold standard for assessing bone marrow status. While the latest guideline suggests the need to omit bone marrow aspiration in patients with no findings on
18
F-fluorodeoxyglucose positron emission tomography (
18
F-FDG PET) based on one retrospective report, there is no study using
18
F-FDG PET/computed tomography (CT). We retrospectively reviewed 26 consecutive, previously untreated, ES/
PNET
patients. We compare the results of bone marrow aspiration and biopsy (BMAB) and those of
18
F-FDG PET/CT in ES/
PNET
patients. All of the 21 patients without metastases on
18
F-FDG PET/CT had negative BMAB. The sensitivity of bone marrow involvement in
bone metastases
positive patients on
18
F-FDG PET/CT was 75% (3/4), and the specificity was 100% (22/22). In addition to the metastatic findings on
18
F-FDG PET/CT, tumor diameter, lactate dehydrogenase level at diagnosis, and the presence or absence of bone metastasis were factors related to bone marrow involvement. It may be a reasonable option to omit BMAB in ES/
PNET
patients with no distant metastasis based on
18
F-FDG PET/CT findings.
...
PMID:Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on
18
F-fluorodeoxyglucose positron emission tomography/computed tomography. 3110 92
